Myeloma Paper of the Day, May 20th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Nice review that proposes genomic-driven approach to selecting therapy for Waldenström macroglobulinemia patients to maximize speed, depth, and duration of responses to BTK inhibitors, and strategies for managing adverse effects.”
Source: Robert Orlowski/X
Optimizing BTK Inhibition in Waldenström Macroglobulinemia
Authors: Shayna Sarosiek and Jorge J. Castillo.4
Other insights by Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
